Lonza Capsules & Health Ingredients
About
Company description
Our experience and expertise have allowed us to become an industry leader in providing innovative, reliable capsules and science-backed ingredients for use in a variety of pharmaceutical and nutraceutical applications around the world.
Lonza Capsules & Health Ingredients comprehensive products and services can be tailored to meet the needs of your development lifecycle by helping you design, optimize and manufacture differentiated dosage form solutions to meet growing and expanding patient and consumer requirements.
Whether you’re looking to stay abreast of nutraceutical market trends, formulate new products, or enhance an existing line, Lonza has the right capsule to help you bring improved products to market faster. Lonza’s Capsugel® capsule portfolio is the product of choice for many manufacturers of food and dietary supplements.
Our leading research-supported ingredients including our UC-II® undenatured type II collagen are formulated to help you innovate, with different dosage form options.
Quick facts
| Primary business activity | Contract Manufacturer |
|---|---|
| Affiliated categories: | Collagen |Contract manufacturing |Encapsulation More |
Recently at
Vitafoods Europe Online and In-Person
1 - 12 May 2023 - Online We were at stand G80 See our Exhibitor Profile See full Exhibitor ListFi India & Hi 2022
21 - 23 September 2022 Bengaluru International Exhibition Centre, Bengaluru We were at stand C54 See our Exhibitor Profile See full Exhibitor List
News about Lonza Capsules & Health Ingredients
4 Sep 2019
BacThera gets regulatory approval
Chr. Hansen and Lonza have received the relevant approvals from anti-trust regulators needed to establish the 50/50 joint venture in the emerging market for live biotherapeutic products, which was originally announced on April 2, 2019.
Read more4 Feb 2019
Lonza reports 9% organic sales growth
Having completed the first full year with Capsugel as a combined company, Lonza has reported a 9% organic (like-for-like) sales, 12% organic core EBITDA and 14% organic core EBIT growth.
Read more